Avidity biosciences announces new precision cardiology development candidates to treat rare genetic cardiomyopathies and provides first look at next-generation technology innovations

Avidity expands  its leading rna delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: aoc 1086 to treat pln cardiomyopathy and aoc 1072 to treat prkag2 syndrome aoc 1072 and aoc 1086 preclinical data demonstrated robust sirna delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac pln mrna and prkag2 mrna avidity introduces next-generation technology innovations demonstrating improved sirna delivery in skeletal muscle and increased durability in preclinical studies aoc 1072 preclinical data will be presented at american heart association (aha) scientific sessions 2024 volume 11 of virtual investor and analyst series today, tuesday, nov. 12 at 8:00 a.m. et san diego , nov. 12, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced it has expanded beyond rare skeletal muscle disorders and is opening up a new therapeutic field, precision cardiology, to address the root cause of genetic diseases of the heart.
RNA Ratings Summary
RNA Quant Ranking